Skip to content

Trial Summary

LYT-100 in Healthy Volunteers and BCRL

Acronym:

LYT-100

ACTRN/NCT /ethics:

NCT04243837

Scientific title:

A Phase 1 Multiple Ascending Dose and Food Effect Study in Healthy Volunteers to Determine the Pharmacokinetics and Maximally Tolerated Dose of Deupirfenidone (LYT-100) Followed by a Randomized Double-Blind Placebo-Controlled Phase 2a in Patients With Breast Cancer-Related Upper Limb Secondary Lymphoedema

Sponsor / Cooperative group:

PureTech

Trial & Patient Characteristics

Cancer TypeBreast
Trial TypeTreatment
PhasePhase I, Phase II
Age Range18 years and older
SexAll
Tumour Stream -
Cancer StageLocally Recurrent or Locally Advanced
Anticipated Start Date2020-03-01
Anticipated End Date2022-06-01

Participating Hospitals

HospitalFlinders Medical Centre
Clinical Trial CoordinatorHannah Adelson
EmailHannah.adelson@sa.gov.au
Phone08 8206 4835
Principal InvestigatorDr Muhammad Nazim Abbas
Recruitment StatusRecruiting